EGFR and neoplasm: Firstly, we added different concentrations of albumin (Figure 3A) or Rituximab (Figure 3B) to the coculture and assessed NK cell degranulation under target-independent conditions in the absence of tumor cells (PMA/Ionomycin activation, left panels, Figures 3A, B) and under ADCC conditions in the presence of Cetuximab and EGFR-positive tumor cells (right panels, Figures 3A, B), respectively.